{"product_id":"aqst-bcg-matrix","title":"(AQST) Aquestive Therapeutics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Aquestive Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAzstarys ADHD franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAzstarys is the clearest growth asset in Aquestive Therapeutics, Inc.'s mix because ADHD is a huge chronic market, with about 7.1 million U.S. children and 15.5 million adults diagnosed, per CDC latest estimates. Its once-daily dosing supports repeat use and better adherence, which helps scale in a condition that often needs long-term treatment. That gives Azstarys the profile of a true BCG \"Star\": high-growth category, branded pull, and room to take share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSympazan clobazam film\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSympazan clobazam film is a Star in Aquestive Therapeutics, Inc.'s BCG view: an oral soluble film for Lennox-Gastaut syndrome, a rare epilepsy affecting about 1 to 2 per 100,000 people. Demand can stay durable through 2025 because rescue and maintenance needs in orphan epilepsy remain high. Its film format gives clear differentiation in a specialty setting where ease of use matters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKYNMOBI apomorphine film\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKYNMOBI apomorphine film fits Stars because Parkinson’s disease affects about 1 million people in the U.S. and nearly 10 million worldwide, and episodic off periods remain a recurring need. Its sublingual film avoids injections and is a practical differentiator for fast rescue dosing. In a niche specialty market, that convenience can support premium pricing and attractive margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOral film delivery platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOral film delivery platform is a Star because one dosage-form engine can support multiple molecules, so Cada new program can reuse the same formulation, manufacturing, and regulatory know-how. That repeatability lowers development friction and can speed launches in specialty pharma, where platform leverage often matters more than one-off products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReusable know-how across molecules\u003c\/li\u003e\n\u003cli\u003eLower development and scale-up risk\u003c\/li\u003e\n\u003cli\u003eBetter leverage in specialty pharma\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnered late-stage programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnered late-stage programs can be a Star for Aquestive Therapeutics, Inc. because partners can fund development and speed launch, which matters in a market where FDA standard reviews often run about 10 months. External commercialization also cuts single-product concentration risk, so one approval can add revenue without Aquestive carrying the full go-to-market cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster scale through partner sales teams\u003c\/li\u003e\n\u003cli\u003eLower launch and concentration risk\u003c\/li\u003e\n\u003cli\u003eEnd-2025 upside needs approval and execution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat upside stays binary: if late-stage assets win approval and the partner executes well, the revenue step-up can be sharp; if not, the bucket stays a small BCG Star with high option value but no cash flow yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAquestive’s Stars Shine in Niche Care With Platform Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc.'s Stars are Azstarys, Sympazan, KYNMOBI, and the oral film platform: they sit in high-need niches with repeat use, clear convenience gains, and share-taking upside. ADHD, rare epilepsy, and Parkinson's off periods all support durable demand, while the film platform can scale across molecules.\u003c\/p\u003e\n\u003cp\u003ePartnered late-stage programs add optionality, since external funding can speed launch and limit cash burn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAzstarys\u003c\/td\u003e\n\u003ctd\u003eADHD scale, once-daily use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSympazan\/KYNMOBI\u003c\/td\u003e\n\u003ctd\u003eOral film edge in niche care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAquestive Therapeutics’ BCG Matrix maps its pipeline and products by growth and market share to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG snapshot for Aquestive Therapeutics, Inc. to pinpoint growth bets and trim portfolio clutter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Aquestive Therapeutics, helping decision-makers verify claims and act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuboxone sublingual film\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuboxone sublingual film is Aquestive Therapeutics, Inc.'s most established buprenorphine-naloxone brand and the clear cash cow in the portfolio. Opioid dependence is a mature, recurring market, so demand stays steady even as growth slows. This franchise has driven the strongest cash-generation profile, with management citing a large, durable U.S. treatment base and continued refill volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved branded film base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApproved branded film base is a Cash Cow because it is already commercialized, so Aquestive Therapeutics, Inc. spends far less on launch and market education than it does on pipeline assets. Mature branded products usually carry steadier margins, and that cash can help fund corporate overhead and R\u0026amp;D. One approved product line can keep paying while new programs stay in development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty and license income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoyalty and license income is a cash cow for Aquestive Therapeutics, Inc. because it monetizes the oral-film platform with low capital needs and little commercial spend. That usually means better cash conversion than development-stage assets, since partner royalties and upfront license fees can flow through with lean overhead. For a BCG view, it is the most efficient way to turn IP into cash.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply and manufacturing agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupply and manufacturing agreements give Aquestive Therapeutics, Inc. steadier cash flow than launch-driven product sales, because contracted production usually fills plant capacity and supports gross margin. For a small-cap specialty company, that matters: fixed costs are spread over more units, so each run can help EBITDA. These revenue streams are also less volatile than new-product launches, which makes them a useful Cash Cow in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher factory utilization can lift margins.\u003c\/li\u003e\n\u003cli\u003eContract revenue is usually more predictable.\u003c\/li\u003e\n\u003cli\u003eStabilizes cash for R\u0026amp;D and launches.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy prescription base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc.'s legacy prescription base fits cash-cow logic: older approved products can keep generating sales even when growth is thin. In 2024, the company still relied on marketed products for recurring prescription demand, which matters more for cash flow than expansion. Stable scripts can fund R\u0026amp;D and new launches without needing big volume gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder products keep cash flowing\u003c\/li\u003e\n\u003cli\u003eGrowth is limited, but stable\u003c\/li\u003e\n\u003cli\u003eUseful for funding new launches\u003c\/li\u003e\n\u003cli\u003eClassic cash-cow behavior\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuboxone Film Powers Aquestive’s Steady Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuboxone film is Aquestive Therapeutics, Inc.'s clearest Cash Cow: a mature, reimbursed opioid-use brand that keeps throwing off repeat prescriptions with low launch spend. Royalty, license, and supply income also fit Cash Cow logic because they monetize the platform with lean capital use and steadier cash conversion. These lines help fund R\u0026amp;D and overhead while growth stays modest.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow stream\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuboxone film\u003c\/td\u003e\n\u003ctd\u003eRecurring demand, mature market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties and supply\u003c\/td\u003e\n\u003ctd\u003eLow capex, steadier cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAquestive Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Aquestive Therapeutics, Inc. BCG Matrix report you’ll receive after purchase. The full document is included with no changes, no watermarks, and no demo content. Once purchased, it’s ready for immediate download, use, or sharing with your team. What you see here is the final file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZuplenz ondansetron film\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZuplenz ondansetron film sits in a generic-heavy anti-nausea market, where low-cost ondansetron tablets, ODTs, and injectables crowd out price. Growth is limited, and share is hard to defend. \u003c\/p\u003e\n\u003cp\u003eThat weak demand profile makes Zuplenz a Dogs asset in Aquestive Therapeutics, Inc.'s BCG Matrix. \u003c\/p\u003e\n\u003cp\u003eIt is a small, low-growth, low-share contributor with little pricing power. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExservan riluzole film\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExservan (riluzole film) sits in a small ALS market: about 5,000 new U.S. ALS diagnoses a year, with roughly 30,000 people living with the disease. That keeps uptake constrained, and a niche oral-film option does not usually scale fast. In BCG terms, it fits low-growth, low-share economics, so it reads as a Dog.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-volume legacy films\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSmall-volume legacy films stay in the Dogs box because older oral-film SKUs often sell in tiny lots and add little to Aquestive Therapeutics, Inc.'s growth. They still soak up regulatory, quality, and supply work, but the payoff is weak; the company's recent revenue has remained only in the tens of millions, which shows how hard these products are to scale. With low volume, even modest upgrade or reformulation costs are hard to recover.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core international sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-core international sales at Aquestive Therapeutics, Inc. fit the \"Dog\" box when local demand is fragmented and share stays small. In BCG terms, assets that do not clear a meaningful share threshold, often under 10%, usually add little to group growth and are better as keep-or-exit bets.\u003c\/p\u003e\n\u003cp\u003eThese channels also face higher route-to-market costs, slower partner control, and weak scale economics. If a market cannot build repeatable volume, the best move is often to prune it or sell it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFragmented markets cap scale\u003c\/li\u003e\n\u003cli\u003eSmall share limits cash impact\u003c\/li\u003e\n\u003cli\u003eKeep-or-exit fits low-return assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-adoption branded remnants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThese low-adoption branded remnants are classic BCG Dogs: weak traction, limited scale, and little sign of a rebound. For Aquestive Therapeutics, Inc., products in this bucket tend to drain sales effort without moving the revenue needle, so extra marketing usually just lifts spend, not demand. If a brand cannot build repeat use or meaningful share, it is better treated as a harvest or exit candidate than a growth bet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeak demand, low share, poor scale.\u003c\/li\u003e\n\u003cli\u003eMarketing rarely fixes the core issue.\u003c\/li\u003e\n\u003cli\u003eBest fit: harvest, trim, or exit.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZuplenz and Exservan Show Aquestive’s Dog-Box Legacy Weakness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZuplenz, Exservan, and other legacy oral-film lines fit the Dogs box for Aquestive Therapeutics, Inc.: low share, slow growth, and weak pricing power. In ALS, about 5,000 new U.S. cases and roughly 30,000 people living with the disease still leave Exservan niche and small.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eDog cue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZuplenz\u003c\/td\u003e\n\u003ctd\u003eGeneric-heavy nausea market\u003c\/td\u003e\n\u003ctd\u003eLow share, weak price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExservan\u003c\/td\u003e\n\u003ctd\u003e~5,000 new ALS cases\/year\u003c\/td\u003e\n\u003ctd\u003eNiche demand, low scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLibervant diazepam film\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLibervant diazepam film meets a real need: FDA approved it on Apr. 26, 2024 for seizure clusters in children ages 2 to 5, a small but high-need rescue market. Adoption now depends on regulatory follow-through, payer access, and launch execution, not just the science. Market share is still the key unknown, so it fits a Question Mark in Aquestive Therapeutics, Inc.'s BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAQST-108 systemic epinephrine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAQST-108 systemic epinephrine fits the Question Mark bucket: it targets a high-need rescue use, but its novel route must still prove real-world adoption. As of 2025, Aquestive Therapeutics, Inc. still needs clear data on prescribing, patient uptake, and repeat use before this franchise can move toward Star status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAQST-305 octreotide film\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAQST-305 octreotide film fits the \"Question Mark\" box because acromegaly is a rare endocrine niche, with prevalence around 40 to 70 cases per million, so the market is real but small. Aquestive Therapeutics, Inc. has not yet shown commercial scale here, and late-stage demand remains unproven. The drug could win on convenience, but adoption risk is still high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAQST-109 oral epinephrine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAQST-109 oral epinephrine sits in a large anaphylaxis market, where about 32 million Americans live with food allergy and epinephrine auto-injectors still dominate emergency care. If Aquestive Therapeutics, Inc. wins approval and adoption, oral dosing could change how patients treat sudden reactions. For now, it is a classic question mark: high upside, but no durable sales yet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge unmet need in anaphylaxis\u003c\/li\u003e\n\u003cli\u003eCould shift emergency allergy care\u003c\/li\u003e\n\u003cli\u003eStill unproven until approval and uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNext-generation complex molecules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc.'s next-generation complex molecules fit a Question Mark: they are the main growth option set, but market share is still not established. These programs need more capital, clinical data, and regulatory wins before they can scale, so upside is real but not proven yet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth potential, low share\u003c\/li\u003e\n\u003cli\u003eNeeds funding and trial success\u003c\/li\u003e\n\u003cli\u003eRegulatory approval is key\u003c\/li\u003e\n\u003cli\u003eCould move to Star if wins stack up\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuest Marks, Big Upside: AQST's Growth Bets Still Need Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc.'s Question Marks are still low-share, high-upside bets: Libervant, AQST-108, AQST-305, and AQST-109 all target clear unmet need, but each still needs approval, access, or adoption to prove scale.\u003c\/p\u003e\n\u003cp\u003eLibervant’s FDA approval on Apr. 26, 2024 and AQST-109’s anaphylaxis angle give the biggest upside, while AQST-305 stays niche and AQST-108 is still early.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLibervant\u003c\/td\u003e\n\u003ctd\u003eApproved\u003c\/td\u003e\n\u003ctd\u003eMarket share unproven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAQST-109\u003c\/td\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003eLarge allergy market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233970888969,"sku":"aqst-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/aqst-bcg-matrix.webp?v=1785711252","url":"https:\/\/dcfanalyst.com\/products\/aqst-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}